Media stories about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intec Pharma earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 44.6478711150897 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research cut shares of Intec Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Roth Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Intec Pharma in a research note on Tuesday, June 26th. Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research note on Thursday, May 24th. HC Wainwright set a $16.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research note on Tuesday, May 22nd. Finally, ValuEngine upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, May 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $12.25.

Shares of Intec Pharma traded down $0.05, hitting $3.95, during mid-day trading on Friday, according to MarketBeat. The company had a trading volume of 87,402 shares, compared to its average volume of 61,827. Intec Pharma has a 12 month low of $3.88 and a 12 month high of $9.80. The stock has a market cap of $131.30 million, a PE ratio of -2.39 and a beta of 1.17.

Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings results on Tuesday, May 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.13). sell-side analysts predict that Intec Pharma will post -1.26 earnings per share for the current year.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Read More: Diversification For Individual Investors

Insider Buying and Selling by Quarter for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.